...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of hyperthermia: The official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group >Long-term survival data of triple modality treatment of stage IIB–III–IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia – an update
【24h】

Long-term survival data of triple modality treatment of stage IIB–III–IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia – an update

机译：放射疗法，化学疗法和高热疗法相结合的IIB–III–IVA期宫颈癌三联疗法治疗的长期生存数据

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Advanced cervical cancer is routinely treated with radiotherapy and cisplatin-containing chemotherapy. Hyperthermia has been shown to improve the results of both radiotherapy and cisplatin. The feasibility of the combination of all three modalities was demonstrated and reported in a study of 68 previously untreated cervical cancer patients in 2005. Long-term follow-up is presented here. Methods: Sixty-eight patients with advanced cervical cancer were prospectively registered in the USA, Norway and the Netherlands, and treated with a combination of radiotherapy (external beam radiotherapy and brachytherapy for a biologically effective dose of at least 86.7?Gy), chemotherapy (at least four courses of weekly cisplatin (40?mg/msup2/sup)) and locoregional hyperthermia (four weekly sessions). Long-term follow-up was gathered and recurrence-free survival (RFS) and overall survival (OS) curves and survival estimates were obtained. Results: Median follow-up was 81 months. Tumours in 28 patients have recurred, 21 of whom have died. Five-year RFS from the day of registration in the study is 57.5% (95%CI: 46.6–71.0) and five-year OS is 66.1% (95%CI: 55.1–79.3). Differences between countries can be explained by patient characteristics. Conclusion: The long-term survival results of the combination of full-dose radiotherapy, chemotherapy and hyperthermia fall well within previous reports for this patient group in randomised trials. The small trial size and lack of randomisation do not permit further interpretation.
机译：背景：晚期宫颈癌通常通过放疗和含顺铂的化学疗法进行治疗。热疗已显示可改善放疗和顺铂的疗效。在2005年对68位先前未接受治疗的宫颈癌患者的研究中，已证明并报告了将这三种方式结合使用的可行性。此处提供了长期随访。方法：前瞻性地在美国，挪威和荷兰对68例晚期宫颈癌患者进行了登记，并采用放疗（外部束放疗和近距离放射治疗，生物有效剂量至少为86.7？Gy），化学疗法（每周至少四个疗程的顺铂（40？mg / m 2 ）和局部热疗（每周四个疗程）。收集长期随访资料，获得无复发生存期（RFS）和总生存期（OS）曲线以及生存期估计值。结果：中位随访时间为81个月。 28例患者的肿瘤复发，其中21例死亡。从研究注册之日起，五年RFS为57.5％（95％CI：46.6-71.0），五年OS为66.1％（95％CI：55.1-79.3）。国家之间的差异可以通过患者特征来解释。结论：随机试验中，全剂量放疗，化学疗法和高热疗法相结合的长期生存结果完全符合该患者组以前的报道。试验规模小，缺乏随机性，无法进一步解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号